Vimarsana
Biggest News Aggregation in the World

Rectal Surgeons News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rectal Surgeons. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rectal Surgeons Today - Breaking & Trending Today

DelveInsight Business Research, LLP: Anal Cancer Market to Showcase Growth at a CAGR of 18% by 2034 - Vimarsana News

DelveInsight Business Research, LLP: Anal Cancer Market to Showcase Growth at a CAGR of 18% by 2034

Currently, several emerging therapies, such as retifanlimab, BMX-001, LCB84, KEYTRUDA (pembrolizumab), and others, are being evaluated in late-stage and mid-stage clinical trials. The successful

CRC Risk Appears Low in Most Patients With Diverticulitis - Vimarsana News

CRC Risk Appears Low in Most Patients With Diverticulitis

Patients with complicated diverticulitis or who aren't current with colorectal cancer screening are at higher risk and should have follow-up colonoscopy to rule it out.

Colorectal cancer: the sneaky one | News, Sports, Jobs - Vimarsana News

Colorectal cancer: the sneaky one | News, Sports, Jobs

Bethesda, Maryland – based National Institutes for Health (NIH) research notes colorectal cancer is America’s third most frequently diagnosed cancer in both

Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University Surgeons Elected to Education Committee of the Association for Academic Surgery - Vimarsana News

Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University Surgeons Elected to Education Committee of the Association for Academic Surgery

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

Intensive Surveillance Cost-Effective in Stage II, III CRC - Vimarsana News

Intensive Surveillance Cost-Effective in Stage II, III CRC

Intensive surveillance after resection on patients with colorectal cancer (CRC) was less cost-effective in stage I but most cost-effective in stage II and III disease.

Source: ajmc.com